IP Library Granted Patent US 8,975,233
Granted Patent B2
US 8,975,233 · App. 13/014,700 · Granted Mar 10, 2015

Methods for renal denervation

Inventors: Emily A. Stein (San Leandro, CA); Kondapavulur T. Venkateswara-Rao (San Jose, CA); Michael A. Evans (Palo Alto, CA)
Assignee: Northwind Medical, Inc.
A61M25/0084A61K31/7048A61B5/0215A61B5/4839A61B2017/22054A61B2017/22061A61B2017/22067A61B2019/5276A61B2019/528A61M25/04A61M2025/0086A61M2025/0087A61M2025/1047
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,975,233
App. No.
13/014,700
Filed
Jan 26, 2011
Granted
Mar 10, 2015
Kind
B2
Art Unit
1649
USPC
514/25
Abstract

Various agents are described to denerve, modulate, or otherwise affect the renal nerves and other neural tissue. Also, various delivery devices are described to deliver an agent locally to the renal nerves. The delivery devices are positioned in the renal artery and penetrate into the wall of the renal artery to deliver the agent to the renal nerves. The delivery devices may be used to deliver the agent according to longitudinal position, radial position, and depth of the renal nerves relative to the renal artery. In addition, various methods are described to denervate, modulate, or otherwise affect the renal nerves and other neural tissue.

Claims (20)

1. A method for killing targeted renal nerve cells in a mammal, the method comprising:

delivering a cardiac glycoside locally to the renal nerve cells in an amount sufficient to potentiate the toxicity effects of an excitatory signal induced by glutamate;

delivering glutamate locally to the renal nerve cells in an amount sufficient to overstimulate the renal nerve cells to promote apoptosis of the renal nerve cells and treat hypertension in the mammal.

2. The method of claim 1 , wherein the cardiac glycoside is digoxin, proscillaridin, or ouabin.

3. The method of claim 1 , further comprising:

delivering digoxin immune Fab to tissue surrounding the renal nerve cells, the digoxin immune Fab being capable of neutralizing any excess cardiac glycoside.

4. The method of claim 1 , further comprising:

delivering an anesthetic to tissue surrounding the renal nerve cells before delivering the cardiac glycoside.

5. The method of claim 1 , further comprising:

delivering saline to tissue surrounding the renal nerve cells to flush any excess cardiac glycoside or glutamate.

6. A method for killing targeted renal nerve cells in a mammal, the method comprising:

delivering a cardiac glycoside locally to the renal nerve cells in an amount sufficient to potentiate the toxicity effects of carbamazepine; and

delivering carbamazepine locally to the renal nerve cells in an amount sufficient to block an action potential and repolarization of the renal nerve cells to kill the renal nerve cells and treat hypertension in the mammal.

7. The method of claim 6 , wherein the cardiac glycoside is digoxin, proscillaridin, or ouabin.

8. The method of claim 6 , further comprising:

delivering digoxin immune Fab to tissue surrounding the renal nerve cells, the digoxin immune Fab being capable of neutralizing any excess cardiac glycoside.

9. The method of claim 6 , further comprising:

delivering an anesthetic to tissue surrounding the renal nerve cells before delivering the cardiac glycoside.

10. The method of claim 6 , further comprising:

delivering saline to tissue surrounding the renal nerve cells to flush any excess cardiac glycoside.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 18, 2014
From: STEIN, EMILY A.; VENKATESWARA-RAO, KONDAPAVULUR T.; EVANS, MICHAEL A.
To: NORTHWIND MEDICAL, INC.
Reel/Frame 033131/0409 →
Continuity (2)
Provisional Application 61336838 · Jan 26, 2010
Related Publication 20110182912A1 · Jul 28, 2011